- Poster presentation
- Open Access
The effects of TeacrineTM, a nature-identical purine alkaloid, on subjective measures of cognitive function, psychometric and hemodynamic indices in healthy humans: a randomized, double-blinded crossover pilot trial
© Habowski et al; licensee BioMed Central Ltd. 2014
- Published: 1 December 2014
- Large Effect Size
- Subjective Measure
- Side Effect Profile
- Systemic Hemodynamic
Aside from caffeine, there is a relative dearth of evidence regarding natural ingredients that enhance subjective “energy” levels. We have studied a unique, naturally occurring purine alkaloid, present in Camellia assamica variety kucha tea (amongst other botanical sources) that acts on both adenosinergic and dopaminergic pathways that appears to influence multiple neurochemical pathways. As a first step in a series of experiments, we examined the effects of TeaCrine™, a nature-identical, chemically equivalent bioactive compound known as theacrine (1,3,7,9-tetramethyluric acid), in humans.
Using a randomized, double-blinded, within-subject (crossover) design, 15 healthy subjects (mean ± SD age, height, wgt, BMI: 28.3 ± 6.1 y, 175.7 ± 11.5 cm, 89.8 ± 21.7 kg, 29.1 ± 4.7) volunteered to ingest 200 mg of TeaCrine™ (Compound Solutions, Inc., Carlsbad, CA) (TC) or Placebo (PLA). Anchored VAS questionnaires were used to detect changes in various aspects of physical and mental energy and performance; side effect profiles, hemodynamics and biochemical markers of safety were also collected over a 3-hr post-dosing period. A subset of 6 subjects underwent a separate 7-day, open-label, repeated dose study comparing 100 mg, 200 mg and 400 mg of TC. Consent to publish the results was obtained from all participants.
The 200 mg dose of TC caused significant improvements in energy (TC: +8.6% vs. PLA: -5.7%, P=0.049) and reductions in fatigue (TC: -6.7% vs. PLA: +5.8%, P=0.04). A trend for improved concentration was also noted (TC: +2.4% vs. PLA: -1.3%, P=0.07). No changes in systemic hemodynamics or side effect profiles were noted. The N=6 cohort study demonstrated moderate to large effect sizes (0.50 to 0.71) with the 200 mg dose of TC over a 7-day period of assessment for the following subjective measures: energy, fatigue, concentration, anxiety, motivation to exercise and libido.
These preliminary data support the benefits of acute TeaCrine™ supplementation on subjective “energy” levels and some indices of mental performance. Future studies are underway to confirm these neurotropic effects and also explore potential benefits of TeaCrine™ on objective measures of cognitive and physical performance, inflammation, pain perception, and functional capacity.
Partial funding for this study was provided by Compound Solutions, Inc (Carlsbad, CA)
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.